Accretion Nutraveda IPO
Bookbuilding IPO | ₹25.00 Cr | Listing at BSE SME
IPO Open
Tue, Jan 27, 2026
IPO Close
Fri, Jan 30, 2026
Price Band
₹122.00 to ₹129.00
Market Cap (Pre-IPO)
₹93.40 Cr
IPO Details
| IPO Date | Jan 27, 2026 to Jan 30, 2026 |
| Listing Date | Tentative: Feb 04, 2026 |
| Face Value | ₹10.00 per share |
| Price Band | ₹122.00 to ₹129.00 |
| Lot Size | 1000 Shares (Minimum: ₹129,000.00) |
| Sale Type | Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Issue Size | ₹25.00 Crores |
| Total Shares Offered | 1,920,000 shares |
| Offer For Sale | 1,920,000 shares |
Accretion Nutraveda IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 9,08,000 (47.29%) |
| Retail Shares Offered | 6,40,000 (33.33%) |
| NII Shares Offered | 2,76,000 (14.37%) |
Accretion Nutraveda IPO Lot Size
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹258,000 |
| Retail (Max) | 2 | 2,000 | ₹258,000 |
| S-HNI (Min) | 3 | 3,000 | ₹387,000 |
| S-HNI (Max) | 7 | 7,000 | ₹903,000 |
| B-HNI (Min) | 8 | 8,000 | ₹1,032,000 |
Accretion Nutraveda Financial Information (Restated Consolidated)
Accretion Nutraveda Ltd.'s revenue increased by 209% and profit after tax (PAT) rose by 218% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 10.86 | 4.64 | 4.06 |
| Total Income | 16.06 | 5.20 | 3.07 |
| Profit After Tax | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.65 | 1.21 | 0.59 |
| NET Worth | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 4.86 | 0.72 | -0.10 |
| Total Borrowing | 3.86 | 2.17 | 1.97 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| ROE (Return on Equity) | 81.22% |
| ROCE (Return on Capital Employed) | 36.98% |
| Debt/Equity | 0.72 |
| RoNW (Return on Net Worth) | 48.85% |
| PAT Margin (Profit After Tax Margin) | 16.33% |
| EBITDA Margin | 22.79% |
| Price to Book Value | 8.76 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 4.91 | 3.61 |
| P/E (x) | 26.27 | 35.75 |
| Promoter Holding | 100.00% | 73.48% |
Company Promoters
- Mr. Mayur Popatlal Sojitra
- Mr. Ankurkumar Shantilal Patel
- Mr. Paraskumar Vinubhai Parmar
- Mr. Hardik Mukundbhai Prajapati
- Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel are the company promoters.
Company Overview
- Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms, including tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels.
- The company operates as a Contract Development and Manufacturing Organization (CDMO), serving both domestic and international markets such as Sri Lanka, Singapore, and the USA. Its products combine classical Ayurvedic principles with modern nutraceutical science to address areas like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.
- Business verticals:
- Domestic Sales & Merchant Exports (Loan License Basis)– contributing 96.62% of total revenue in FY 2024-25.
- Direct Exports– Contributing 38%, showing consistent growth.
- It has a manufacturing facility in Gujarat covers about 10,763 sq. ft., equipped with modern infrastructure, including 13 air handling units, separate processing areas, and quality control systems. The facility is GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certified, with an FSSAI license.
Company Strengths
- Experienced promoters and management Team
- Diverse product portfolio
- Commitment to quality standards
- Relationships with clients and suppliers
- Established business process and management framework
Use of Proceeds
| 1) | Purchase of Machineries for Automation in existing Manufacturing unit | 4.22 |
| 2) | Purchase of Machineries for New Manufacturing Setup | 8.03 |
| 3) | Funding working capital requirements of our company | 5.50 |
| 4) | General corporate purposes |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Accretion Nutraveda IPO Peer Comparison
Accretion Nutraveda peer comparison with similar listed entities. (As on March 31, 2025)| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Accretion Nutraveda Ltd. | 7.19 | 7.19 | 14.72 | 0.00 | 48.85 | 0.00 | - |
| Walpar Nutritions Ltd. | 1.80 | 1.80 | 13.65 | 23.94 | 11.27 | 3.31 | - |
| Influx Healthtech Ltd. | 7.31 | 7.31 | 5.31 | 25.93 | 36.72 | 37.80 | - |
Quick Info
| Sector | Healthcare and Pharmaceutical |
| Exchange | BSE SME |
| Market Cap (Pre-IPO) | ₹93.40 Cr |
| GMP | 0.00 |
Important Dates
| IPO Open | Jan 27, 2026 |
| IPO Close | Jan 30, 2026 |
| Allotment Date | Feb 02, 2026 |
| Credit to Demat | Feb 03, 2026 |
| Listing Date | Tentative: Feb 04, 2026 |
Lead Manager(s)
Sobhagya Capital Options Pvt.Ltd.
Registrar
Kfin Technologies Ltd.
04067162222, 04079611000
Description
Accretion Nutraveda IPO is a book build issue of ₹24.77 crores. The issue is entirely a fresh issue of 0.19 crore shares of ₹24.77 crore.
Accretion Nutraveda IPO opens for subscription on Jan 27, 2026 and closes on Jan 30, 2026. The allotment for the Accretion Nutraveda IPO is expected to be finalized on Feb 2, 2026. Accretion Nutraveda IPO will list on BSE SME with a tentative listing date fixed as Feb 4, 2026.
Accretion Nutraveda IPO price band is set at ₹122 to ₹129 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,58,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹3,87,000.